Corvex Management LP Decreased Its Position in Medicines Co (MDCO) by $19.73 Million

March 14, 2018 - By Darrin Black

Investors sentiment decreased to 0.78 in Q3 2017. Its down 0.44, from 1.22 in 2017Q2. It dropped, as 32 investors sold MDCO shares while 64 reduced holdings. 19 funds opened positions while 56 raised stakes. 85.15 million shares or 1.36% less from 86.33 million shares in 2017Q2 were reported. Corvex Mngmt LP holds 3.36% or 2.41 million shares in its portfolio. 123,925 are held by Morgan Stanley. First Mercantile invested 0.02% of its portfolio in The Medicines Company (NASDAQ:MDCO). Louisiana State Employees Retirement Systems has invested 0.05% in The Medicines Company (NASDAQ:MDCO). Quantbot Technology L P, New York-based fund reported 4,622 shares. Slate Path LP reported 1.11 million shares. Antipodean Advisors Limited Liability Co has 5.5% invested in The Medicines Company (NASDAQ:MDCO). Zurcher Kantonalbank (Zurich Cantonalbank) holds 0% of its portfolio in The Medicines Company (NASDAQ:MDCO) for 2,753 shares. Federated Investors Inc Pa holds 141,759 shares. Moreover, Stevens Mgmt LP has 0.01% invested in The Medicines Company (NASDAQ:MDCO) for 8,477 shares. Highvista Strategies Lc holds 268,240 shares. State Of Wisconsin Investment Board invested in 0.01% or 52,000 shares. Hall Laurie J Trustee accumulated 930 shares. Texas Permanent School Fund invested 0.02% in The Medicines Company (NASDAQ:MDCO). Whittier Tru Of Nevada Incorporated owns 1,037 shares for 0% of their portfolio.

Since December 7, 2017, it had 1 buy, and 1 insider sale for $1.60 million activity. ESHELMAN FREDRIC N had bought 200,000 shares worth $5.31 million.

Keith Meister decreased its stake in Medicines Co (MDCO) by 18.11% based on its latest 2017Q3 regulatory filing with the SEC. Corvex Management Lp sold 533,227 shares as the company’s stock declined 20.30% while stock markets rallied. The hedge fund run by Keith Meister held 2.41 million shares of the major pharmaceuticals company at the end of 2017Q3, valued at $89.30M, down from 2.94 million at the end of the previous reported quarter. Corvex Management Lp who had been investing in Medicines Co for a number of months, seems to be less bullish one the $2.52 billion market cap company. The stock decreased 0.98% or $0.34 during the last trading session, reaching $34.43. About 658,255 shares traded. The Medicines Company (NASDAQ:MDCO) has risen 16.70% since March 14, 2017 and is uptrending. It has by 0.00% the S&P500.

Analysts await The Medicines Company (NASDAQ:MDCO) to report earnings on April, 25. They expect $-0.75 earnings per share, up 47.92 % or $0.69 from last year’s $-1.44 per share. After $-2.19 actual earnings per share reported by The Medicines Company for the previous quarter, Wall Street now forecasts -65.75 % EPS growth.

More notable recent The Medicines Company (NASDAQ:MDCO) news were published by: which released: “The Medicines Company Reaches Enrollment Target for ORION-9 Ahead of Schedule” on February 20, 2018, also with their article: “The Medicines Company Reaches Enrollment Target for ORION-10 Ahead of Schedule” published on March 08, 2018, published: “In Cholesterol Drug Battle, Sanofi/Regeneron Jolt Prospects Of The Medicines …” on March 12, 2018. More interesting news about The Medicines Company (NASDAQ:MDCO) were released by: and their article: “The Medicines Company: The Upcoming ODYSSEY Trial Results Could Make It A More …” published on March 08, 2018 as well as‘s news article titled: “Activist Alex Denner to gain board control at Medicines Co.” with publication date: March 01, 2018.

The Medicines Company (NASDAQ:MDCO) Ratings Coverage

Among 11 analysts covering The Medicines Co (NASDAQ:MDCO), 10 have Buy rating, 0 Sell and 1 Hold. Therefore 91% are positive. The Medicines Co had 36 analyst reports since August 28, 2015 according to SRatingsIntel. The company was maintained on Monday, July 17 by Citigroup. The firm has “Outperform” rating given on Monday, November 16 by RBC Capital Markets. On Tuesday, July 25 the stock rating was maintained by H.C. Wainwright with “Buy”. Oppenheimer upgraded it to “Buy” rating and $50.0 target in Wednesday, November 29 report. As per Monday, August 14, the company rating was maintained by Citigroup. Cowen & Co maintained it with “Buy” rating and $54.0 target in Tuesday, October 10 report. The company was maintained on Monday, August 28 by Oppenheimer. The stock of The Medicines Company (NASDAQ:MDCO) earned “Buy” rating by Leerink Swann on Monday, August 31. JP Morgan maintained The Medicines Company (NASDAQ:MDCO) on Saturday, August 29 with “Buy” rating. Chardan Capital Markets maintained it with “Buy” rating and $85.0 target in Wednesday, August 30 report.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: